Omodamola Aje, MD, has built a social media platform to provide women with the tools they need to ask their doctors informed questions and help guide decisions in their treatment, from menopause to hypothyroidism. Aje is using her platform to not only help build a sense of community, but to cut through the rampant misinformation...
On behalf of the Endocrine Society’s Oncoendocrinology Special Interest Group, Ling Zhu, MBBChir, discusses her recent paper that addressed “the gap in standardized nomenclature, clinical, laboratory and radiological evaluations, and management principles of endocrine- immune-related adverse events (E-irAEs).” She also talks to corresponding author, Afreen Shariff, MD, about the need for nomenclature, the nature of...
Every month is diabetes awareness month at the Endocrine Society. In the United States, November has been set aside for this purpose, allowing healthcare organizations, advocates, and providers to draw attention to this disease that affects millions of people. I’d like to take this opportunity to recap some of the diabetes-related initiatives at the Endocrine...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
A recently published Scientific Statement sheds light on new and improved treatment options for type 1 diabetes. Endocrine News speaks with first author Aaron W. Michels, MD, about the Statement’s implications and why this is an exciting time in type 1 diabetes research. In July, the Endocrine Society published a Scientific Statement that highlights potential...
On behalf of the Endocrine Society’s Early-Career Special Interest Group (SIG), Milay Luis Lam, MD talks with Early-Career SIG steering group member, Manasi Shah, MD, on bringing science to the transplant bedside and discusses her endocrine journey from her native Mumbai, India, to conducting clinical trials in the U.S. You could say that treating people...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease On Nov. 6, Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine...
A major shift is underway in women’s endocrine health that is changing how the medical community approaches Polycystic Ovary Syndrome (PCOS) and its link to cardiovascular risk. Recent findings published in the European Journal of Endocrinology, titled “Hyperandrogenaemia, Polycystic Ovary Syndrome, and Physical Fitness in Women—a Northern Finland Birth Cohort Study,” stem from a large...
Every month is diabetes awareness month at the Endocrine Society. In the United States, November has been set aside for this purpose, allowing healthcare organizations, advocates, and providers to draw attention to this disease that affects millions of people. I’d like to take this opportunity to recap some of the diabetes-related initiatives at the Endocrine...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
